Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment

Metaplastic breast carcinoma (MBC) differs from classic invasive ductal carcinomas regarding incidence, pathogenesis, and prognosis. The purpose of this study was to compare patients with MBC with clinicopathologic and treatment-matched patients with triple-negative breast carcinoma (TNBC) in terms...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2015-12, Vol.94 (52), p.e2341-e2341
Main Authors: Aydiner, Adnan, Sen, Fatma, Tambas, Makbule, Ciftci, Rumeysa, Eralp, Yesim, Saip, Pinar, Karanlik, Hasan, Fayda, Merdan, Kucucuk, Seden, Onder, Semen, Yavuz, Ekrem, Muslumanoglu, Mahmut, Igci, Abdullah
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents - therapeutic use
Bridged-Ring Compounds - therapeutic use
Carcinoma, Ductal, Breast - epidemiology
Carcinoma, Ductal, Breast - pathology
Carcinoma, Ductal, Breast - therapy
Disease-Free Survival
Female
Humans
Incidence
Mastectomy - adverse effects
Mastectomy - methods
Mastectomy - statistics & numerical data
Middle Aged
Neoplasm Invasiveness
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Observational Study
Prognosis
Retrospective Studies
Taxoids - therapeutic use
Triple Negative Breast Neoplasms - epidemiology
Triple Negative Breast Neoplasms - pathology
Triple Negative Breast Neoplasms - therapy
Turkey - epidemiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metaplastic breast carcinoma (MBC) differs from classic invasive ductal carcinomas regarding incidence, pathogenesis, and prognosis. The purpose of this study was to compare patients with MBC with clinicopathologic and treatment-matched patients with triple-negative breast carcinoma (TNBC) in terms of response to treatment, progression, and survival.Fifty-four patients with MBC and 51 with TNBC, who were treated at Istanbul University, Institute of Oncology, between 1993 and 2014, were included in the study. After correctly matching the patients with 1 of the 2 groups, they were compared to determine differences in response to treatment, disease progression, clinical course, and survival.At a median follow-up of 28 months, 18 patients (17.1%) died and 27 (25.5%) had disease progression. Metaplastic histology was significantly correlated with worse 3-year progression-free survival (PFS) (51 ± 9% vs. 82 ± 6%, P = 0.013) and overall survival (OS) (68 ± 8% vs. 94 ± 4%, P = 0.009) compared with TNBC histology. Patients who received taxane-based chemotherapy (CT) regimens or adjuvant radiotherapy had significantly better PFS (P = 0.002 and P 
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000002341